# Diagnosis of Human Leptospirosis: High Resolution Melting Analysis for Direct Detection of *Leptospira* in the Early Stage of the Disease in a Clinical Setting

Lisa M. Esteves<sup>1</sup>, Sara M. Bulhões<sup>1</sup>, Claudia C. Branco<sup>1,2,3</sup>, Teresa Carreira<sup>4</sup>, Maria L.
Vieira<sup>4</sup>, Maria Gomes-Solecki<sup>5</sup> & Luisa Mota-Vieira<sup>1,2,3\*</sup>

5

# 6 **Affiliations**:

7 <sup>1</sup>Molecular Genetics and Pathology Unit, Hospital of Divino Espírito Santo of Ponta Delgada, EPER, São Miguel Island, Azores, Portugal. <sup>2</sup>Azores Genetics Research Group, 8 Instituto Gulbenkian de Ciência, Oeiras, Portugal. <sup>3</sup>Centre for Biodiversity, Functional and 9 Integrative Genomics, Faculty of Sciences, University of Lisboa, Portugal. <sup>4</sup>Global Health 10 and Tropical Medicine (GHTM), Instituto de Higiene e Medicina Tropical (IHMT), 11 Universidade Nova de Lisboa (UNL), Portugal. <sup>5</sup>Department of Microbiology, Immunology 12 and Biochemistry, The University of Tennessee Health Science Center, Memphis, 13 Tennessee, USA. 14

15

## 16 **\*Corresponding author**:

- 17 Luisa Mota-Vieira, PhD
- 18 Molecular Genetics and Pathology Unit
- 19 Hospital of Divino Espírito Santo of Ponta Delgada, EPER
- 20 Avenida D. Manuel I
- 21 9500-782 Ponta Delgada
- 22 São Miguel Island, Azores Portugal
- 23 Phone: +351 296 203 531
- 24 Fax: +351 296 203 090
- 25 E-mail: Luisa.MQ.Vieira@azores.gov.pt

26 Currently, the direct detection of *Leptospira* infection can be done in clinical laboratories by a conventional nested polymerase chain reaction method (nested PCR), which is 27 labourious and time-consuming. To overcome these drawbacks, we tested a set of paired 28 samples of serum and urine from 202 patients presenting at a hospital located in an area 29 endemic for leptospirosis using high resolution melting (HRM). The results were compared 30 with those obtained by nested PCR for direct detection of the pathogen in both specimens 31 32 and with the gold standard test used for indirect detection of anti-Leptospira antibodies in serum (the microscopic agglutination test, MAT). The HRM assay results were positive for 33 34 46/202 (22.7%) samples, whereas 47/202 (23.3%) samples were positive by nested PCR. As expected in recently infected febrile patients, MAT results were positive in only 3/46 35 (6.5%) HRM-positive samples. We did a unique comparative analysis using a robust 36 37 biobank of paired samples of serum and urine from the same patient to validate the HRM assay for molecular diagnosis of human leptospirosis in a clinical setting. This assay fills a 38 void unmet by serologic assays as it can detect the presence of *Leptospira* in biological 39 samples even before development of antibody takes place. 40

#### 42 Introduction

Leptospirosis is a worldwide zoonotic and neglected infectious disease caused by 43 pathogenic bacteria of the *Leptospira* genus from the family Leptospiraceae<sup>1</sup>. This disease 44 is known for its endemicity mainly in countries with a humid tropical or subtropical climate, 45 such as Brazil, India and Portugal (Azores Islands)<sup>2</sup>. The infection is associated with a 46 variety of clinical manifestations, ranging from flu-like symptoms to multiple organ failure 47 48 and death. As a result, the disease is often difficult to diagnose clinically, and laboratory support is essential<sup>3</sup>. Treatment with appropriate antibiotics should be initiated as early as 49 50 possible after laboratory confirmation; however, the majority of patients suspected to have leptospirosis are treated empirically with broad-spectrum antibiotics effective against most 51 bacteria before a definitive diagnosis is established. At the Hospital of Divino Espírito Santo 52 of Ponta Delgada (HDES), located on São Miguel Island (Azores), Leptospira infection is 53 confirmed in the laboratory by identifying the presence of specific fragments of Leptospira 54 DNA in patient samples (serum and urine) through conventional nested polymerase chain 55 reaction (nested PCR)<sup>4,5</sup>. This method is time-consuming (it takes approximately 5 hours) 56 and is sometimes too slow to support the clinical decision for antibiotic therapy. 57

Current techniques to detect Leptospira infection are evolving from conventional 58 PCR to real-time PCR, which is faster, tends to have higher sensitivity and specificity at 59 detecting pathogenic *Leptospira* species and is performed in a closed system that reduces 60 the risk of DNA cross-contamination<sup>6</sup>. An emerging technique for clinical diagnosis is high 61 resolution melting (HRM) analysis. HRM was first described by Carl Wittwer's group for 62 mutation screening<sup>7</sup>, and the underlying principle is the generation of different melting curve 63 profiles due to sequence variations in double-stranded DNA. HRM is typically performed 64 with a real-time PCR instrument immediately after PCR. Advantages of this method include 65 a rapid turn-around time (less than 2hr), a closed-tube format that significantly reduces 66

contamination risk, high sensitivity and specificity, low cost and, unlike other methods, no
 sample processing or separations after PCR<sup>8</sup>. Furthermore, HRM is a non-damaging
 method that enables the subsequent analysis of the sample by other methods, such as
 DNA sequencing or gel electrophoresis<sup>9</sup>.

In a clinical diagnostic context, HRM has been validated for the detection of 71 oncogene mutations<sup>10</sup>, human malaria diagnosis<sup>11</sup>, species differentiation and genotyping 72 within microbial species<sup>12</sup>, but not diagnosis of human leptospirosis. Recently, two studies 73 described an HRM method for typing Leptospira strains at the species and subspecies 74 75 levels<sup>13,14</sup>; the method described in the first study can accurately discriminate L. interrogans, L. kirschneri, L. borgpetersenii and L. mayottensis with a specificity and 76 reproducibility of 100% and less than 0.5% variation in the melting temperature (T<sub>m</sub>) 77 coefficient<sup>13</sup>. The second study describes a PCR-HRM assay that targets the 16S ribosomal 78 gene to identify *Leptospira* species from isolated cultures<sup>14</sup>. However, in both studies, HRM 79 was not evaluated in patient samples as a clinical diagnostic test for human leptospirosis. 80

The aim of the present work was to evaluate a diagnostic assay for human leptospirosis capable of providing timely laboratory results on the same day the patient is seen at the emergency room. To address this unmet need, we used a robust biobank of paired serum and urine samples and evaluated the accuracy of HRM analysis as a clinical diagnostic tool for direct detection of *Leptospira* in the very early stage of human leptospirosis.

87

#### 88 METHODS

Ethical considerations. The present study followed international ethical guidelines and
was evaluated and approved by the Health Ethics Committee of the HDES (Ref.
HDES/CES/159/2009). The analysis of retrospective samples (serum and urine) from

patients suspected of having leptospirosis was exempted from the need to obtain informed
consent under the regulations of the Portuguese Data Protection Commission – law
12/2005 article 19, number 6 (https://www.cnpd.pt/bin/orientacoes/DEL227-2007ESTUDOS-CLINICOS.pdf, accessed February 22, 2017).

96

Study design. The present work is a retrospective hospital-based study that includes 97 98 samples from patients suspected of leptospirosis infection who mainly presented at the Emergency Department (n = 167, 82.7%) of the Hospital of Divino Espírito Santo of Ponta 99 100 Delgada in São Miguel, Azores, a Portuguese island in which leptospirosis is endemic. A total of 202 patients were investigated from January 2015 to June 2016 (Supplementary 101 Table S1). The mean patient age was 48.2 (±16.4) years. Higher rates of males (89.6%), 102 103 farmers (20.3%) and unemployed persons (13.4%) were observed in the study population. Clinical diagnosis by the attending physician was based on signs and symptoms of 104 leptospirosis, as previously described<sup>15,16</sup>. Briefly, physicians looked for epidemiological 105 context, such as rural activities and direct contact with contaminated areas (rat urine), and 106 clinical manifestations, including fever, myalgia, jaundice and coluria, before collecting 107 biological samples (serum and urine) for molecular detection/confirmation of Leptospira 108 spp. We centrifuged all sera and urine samples at 2000 rpm for 10 minutes. Bacterial DNA 109 was automatically extracted from 400 µl of independent samples of serum (S1 and S2) and 110 111 urine (U1 and U2) from each patient using the BioRobot EZ1 Advanced System (Qiagen). A total of 808 samples were processed. 112

113

Reference molecular test (conventional nested PCR). Conventional nested PCR was considered the reference standard for *Leptospira* spp. DNA detection in the present study. After automatic bacterial DNA extraction, the *rrs* (16S rRNA) gene was amplified as

previously described<sup>4,5</sup> by conventional nested PCR in a Biometra® T-Gradient thermal 117 cycler. We used two primer sets: forward-A 5'-GGCGGCGCGTCTTAAACATG-3' and 118 5'-TTCCCCCCATTGAGCAAGATT-3' for the first PCR; nested-A 5'-119 reverse-B TGCAAGTCAAGCGGAGTAGC-3' and nested-B 5'-TTCTTAACTGCTGCCTCCCG-3' for 120 the nested PCR. The first PCR reaction contained 5 µl of bacterial DNA, 10 µM primers A 121 and B, 100 µM dNTPs (Promega), 25 nM MgCl<sub>2</sub> (Qiagen), 1X Q-Solution (Qiagen), 1X 122 buffer (Qiagen), 5 U of HotStart Tag (Qiagen) and RNase-free water to a final volume of 50 123 µl. The PCR programme started with an enzyme activation step at 95°C for 15 minutes; 124 125 proceeded with 30 cycles of 94°C for 1 minute, 63°C for 1 minute and 72°C for 1 minute; and ended with a final extension step at 72°C for 10 minutes. The nested PCR (2<sup>nd</sup> round) 126 used 5 µl of the first-round PCR product and 10 µM nested-A and nested-B primers. The 127 128 first cycle consisted of denaturation at 95°C for 15 minutes, followed by 30 cycles of denaturation at 94°C for 1 minute, primer annealing at 63°C for 1 minute, and extension at 129 72°C for 1 minute, with an additional step at 72°C for 10 minutes at the end, resulting in a 130 292 bp fragment. Amplified Leptospira DNA was visualized in an UV transilluminator 131 instrument (BioRad) after agarose gel electrophoresis (3%). A patient was defined as 132 having a laboratory-confirmed case of leptospirosis when Leptospira DNA was detected in 133 at least one serum (S1 or S2) or urine (U1 or U2) sample. 134

135

136 High resolution melting (HRM) analysis. Primer pairs for HRM analysis were chosen according to the results obtained by Naze et al<sup>13</sup>. We used the following LFB1 F/R and 137 G1/G2 primers to amplify the Ifb1 and secY genes, respectively: LFB1-F 5'-138 139 CATTCATGTTTCGAATCATTTCAAA-3' and LFB1-R 5'-GGCCCAAGTTCCTTCTAAAAG-3', and G1 5'-CTGAATCGCTGTATAAAAGT-3' G2 5'-140 and GGAAAACAAATGGTCGGAAG-3'. The 15 µl reactions contained 7.5 µl of 2X Type-it HRM 141

master mix (Qiagen), 0.7 µM final concentration of each primer (TibMolBiol), 3.75 µl of extracted bacterial DNA, and RNase-free water to a final volume of 15 µl. We performed the following amplification protocol in the 7500 Fast Real-Time PCR instrument (Applied Biosystems): denaturation at 95°C for 5 minutes, followed by 45 cycles of 95°C for 10 seconds, 55°C for 30 seconds, and 72°C for 10 seconds. These conditions were used for both primer sets. After PCR cycling, the samples were heated from 70°C to 95°C with continuous data acquisition.

We used six pathogenic Leptospira reference cultures provided by the Portuguese 149 150 Reference Laboratory for Leptospirosis (at the Instituto de Higiene e Medicina Tropical, IHMT, of the Universidade Nova de Lisboa) as positive controls: 4 strains belonging to L. 151 interrogans serogroup (sg) Icterohaemorrhagiae, L. borgpetersenii sg Ballum, L. kirschneri 152 153 sg Cynopteri and L. noguchii sg Panama and 2 human Azorean isolates<sup>4</sup> belonging to L. interrogans serovar (sv) Copenhageni of Icterohaemorrhagiae sg (human isolate 1) and L. 154 155 borgpetersenii sv Arborea of Ballum sg (human isolate 6). Melting curve plots were generated and analysed using High Resolution Melt software v3.0.1 (Applied Biosystems) 156 to determine average melting temperature (T<sub>m</sub>) for each *Leptospira* spp. 157

158

**HRM benchmarking confirmation by Sanger sequencing.** To validate the HRM analysis, 159 we selected 18 biological specimens (13 serum and 5 urine samples) from laboratory-160 161 confirmed leptospirosis patients, including the sample positive by nested PCR and negative by HRM analysis. As reference DNA sequences, we used two Leptospira spp. (L. 162 interrogans sg Icterohaemorrhagiae and L. borgpetersenii sg Ballum) and two human 163 164 isolates. Amplified DNA products of Leptospira obtained by nested PCR were purified using the QIAquick PCR Purification Kit (Qiagen) according to the manufacturer's instructions. 165 Sequencing was performed using the nested-A and nested-B primer pair with the BigDye 166

Terminator v1.1 cycle sequencing kit (Applied Biosystems) under the following conditions: 2 167 µl of ready reaction mix, 4 µl of BigDye sequencing buffer, 3.2 pmol of each primer pair, 7 168 ng of DNA, and RNase-free water to a final reaction volume of 20 µl. The cycling 169 programme included an initial denaturation step at 96°C for 1 minute, followed by 25 cycles 170 of 96°C for 10 seconds, 50°C for 5 seconds and 60°C for 4 minutes, in a GeneAmp® PCR 171 System 2700 (Applied Biosystems). The sequencing products were purified with a BigDye 172 173 XTerminator® Purification Kit (Applied Biosystems) and separated by capillary electrophoresis in an automated sequencer (ABI 3130 Genetic Analyzer, Applied 174 175 Biosystems) with a 36 cm capillary and POP-7<sup>™</sup> polymer according to the manufacturer's instructions. Data were analysed with Sequencing Analysis software v5.3.1 (Applied 176 Biosystems). Sequences were aligned using Bioedit<sup>™</sup> software v7.0.0. 177

178

Microscopic agglutination test (MAT). A total of 46 serum samples evaluated as positive 179 by the molecular approach were aliquoted and stored at -20°C for further detection of 180 anti-Leptospira spp. antibodies by MAT. Additionally, 20 negative serum samples were 181 selected as controls. MAT was performed at the Portuguese Reference Laboratory for 182 Leptospirosis (IHMT, Universidade Nova de Lisboa) using a battery of 25 live pathogenic 183 serovars (including 4 Azorean isolates) representative of 15 serogroups of pathogenic 184 Leptospira and a saprophytic serovar of L. biflexa as an internal control. Samples were 185 initially screened at a 1:40 dilution, and reactive sera were further diluted in a 2-fold series 186 to the endpoint, defined as the highest serum dilution that agglutinated at least 50% of 187 188 leptospires. For the Azorean endemic region, samples were considered positive when titres were 1:160 or greater, not conclusive when titres were below 1:160 (cut-off), and negative 189 when no agglutination was observed. 190

191

192 Statistical analysis. The nested PCR test was used as the reference molecular test to calculate the sensitivity, specificity, positive and negative predictive values (PPV and NPV), 193 and overall accuracy [with the 95% confidence interval (CI)]. Calculations were performed 194 using Vassar College's VassarStats Website for Statistical 195 Computation (http://www.vassarstats.net, last accessed November 10, 2017). To determine whether 196 there was a significant difference between the diagnostic tests for Leptospira detection, 197 198 data were analysed by McNemar's test, and p < 0.05 indicated statistical significance. The Standards for Reporting of Diagnostic Accuracy (STARD) statement was followed when 199 200 reporting the results of the present study<sup>17</sup>.

201

#### 202 **Results**

203 HRM assay. The HRM assay was able to successfully distinguish 4 Leptospira spp. (L. interrogans sg Icterohaemorrhagiae, L. borgpetersenii sg Ballum, L. kirschneri sg Cynopteri 204 and L. noguchii sg Panama) and the 2 human Leptospira isolates (HI1 and HI6). As shown 205 in the derivative plot (Fig. 1), the LFB1 F/R and G1/G2 primer sets produced distinct melting 206 curve profiles for reference Leptospira strains of L. interrogans and L. borgpetersenii spp. 207 that matched those of the human Leptospira isolates (HI1 and HI6) of the same species. 208 The T<sub>m</sub> values obtained for LFB1 F/R were 80.71°C (*L. interrogans*), 81.84°C (*L. noguchii*), 209 82.31°C (L. kirschneri) and 83.26°C (L. borgpetersenii), and those for G1/G2 were 78.61°C 210 211 (L. noguchii), 79.10°C (L. interrogans), 79.19°C (L. kirschneri) and 81.50°C (L. borgpetersenii). Moreover, these results were reproducible across 10 independent melt 212 213 curve runs.

214

215 **HRM screening of samples from patients suspected of having leptospirosis.** We 216 screened 808 clinical specimens (404 serum and 404 urine; paired samples from 202 217 patients) using HRM analysis. The average T<sub>m</sub> with the LFB1 F/R primers was 80.94°C in 28 (60.9%) and 83.84°C in 16 (39.1%) patients (Supplementary Table S2). The average Tm 218 with the G1/G2 primers was 79.36°C in 28 (60.9%) and 81.82°C in 18 (39.1%) patients. For 219 both primer sets, we found one clinical sample to be positive by nested PCR and negative 220 by HRM. The T<sub>m</sub> obtained with *Leptospira* spp. and the melting curve profile results were 221 consistent for the remaining patient samples (Fig. 2). We clustered the melting curves in 222 223 two groups and identified the Leptospira spp. in the patient samples by comparing the Tm 224 values to those of the six *Leptospira* positive controls.

225

Kinetics of disease progression based on Leptospira detection. We evaluated paired 226 serum and urine samples from 202 patients clinically suspected of having Leptospira spp. 227 228 infection by nested PCR and HRM (Table 1). The nested PCR results were positive for 23.3% (47/202) patients and negative for 76.7% (155/202). Using HRM, the results were 229 positive for 22.7% (46/202) patients and negative for 77.2% (156/202). The discrepant 230 result between the two molecular assays was confirmed to be a false positive by 231 sequencing (see below). HRM produced conclusive results in about half of the time (~2hr) 232 needed to generate nested PCR results (usually ~5hr). 233

Based on the results of the laboratory-confirmed leptospirosis cases (n = 46), we 234 established the kinetic profiles of disease progression (Table 2). Profile A characterizes 235 236 patients who had a positive molecular result in serum and a negative result in urine, which represents early dissemination of *Leptospira* in blood. In Profile B patients were positive in 237 both serum and urine, which represents the transit of Leptospira infection to the kidney and 238 239 other tissues. Profile C corresponds to patients who were positive in urine and negative in serum, which represents the *Leptospira* excretion stage. The highest percentage of patients 240 analysed by nested PCR (60.9%) and HRM (47.8%) fell under profile B, positive for both 241

serum and urine. The profile analysis also revealed differences between HRM and MAT,
which is in accordance with the kinetics of leptospirosis progression.

244

Sequencing analysis. To benchmark *Leptospira* detection by HRM analysis, we performed 245 Sanger sequencing (Fig. 3). The obtained bacterial DNA sequences confirmed the positive 246 HRM results in 17 clinical samples. One sample (#18) was positive in the urine by nested 247 248 PCR but negative by HRM. This sample was assessed twice by sequencing, HRM and nested PCR, and the sequence had a 97% match to Collinsella aerofaciens, which is found 249 250 predominantly in the human gut. For the remaining samples (17/18), we observed a perfect match with the reference sequences regarding T<sub>m</sub> values, melting curve profiles, and 251 252 sequencing data.

253

Microscopic agglutination test (MAT). MAT results revealed that of the 46 nested PCRpositive patients, only 3 presented specific anti-*Leptospira* antibodies (6.5%), and 3 presented anti-*Leptospira* antibodies below the cut-off titre adopted by the Portuguese Reference Laboratory for Leptospirosis in the Azorean endemic region (Table 3).

258

Analytical specificity and sensitivity of HRM. To validate the HRM analysis as a 259 diagnostic method for *Leptospira* spp. detection, we assessed the accuracy parameters by 260 261 comparing the results of nested PCR (reference molecular test) after sequencing with those obtained by HRM (Table 4). Of the 46 patients who were positive for leptospirosis by nested 262 PCR, 46 had a positive HRM result, for a sensitivity of 1.00 (95% CI: 0.90–1.00). Moreover, 263 264 of the 156 patients who were negative for leptospirosis by nested PCR, 156 had a negative HRM result, for a specificity of 1.00 (95% CI: 0.97-1.00). The PPV and NPV were 1.00 265 (95% CI: 0.90-1.00) and 1.00 (95% CI: 0.97-1.00), respectively. Overall, HRM accuracy 266

was 100%. Together, these results confirm and validate the accuracy of HRM as a clinical
diagnostic test for human leptospirosis.

269

Comparison between HRM and other molecular PCR and serological diagnostic 270 assays for leptospirosis. The current study is the first one to present 100% accuracy 271 values - specificity, sensitivity, Positive Predictive Values (PPV) and Negative Predictive 272 Values (NPV) - for a molecular PCR method, validating the HRM as the best test to be 273 implemented in a clinical setting. No other molecular test has provided PPVs and NPVs 274 (Table 4). Compared with serological methods, HRM has the highest diagnostic value as it 275 can be used to detect Leptospira directly in biological samples collected in the first days of 276 277 the infection, making this test the most reliable to inform treatment decisions for hospitalized patients and patients seen in emergency rooms or clinics (Table 5). 278

279

#### 280 Discussion

In this study, the HRM assay was validated for the accurate detection of *Leptospira* DNA in 281 282 biological samples from patients presenting in the emergency room of a hospital in the Azorean island of São Miguel, a Portuguese region endemic for leptospirosis. Among 202 283 human patients suspected of having leptospirosis, 46 tested positive (22.7%) by both 284 nested PCR and HRM; among these patients, only 3 tested positive (6.5%) by MAT. 285 Melting curve profiles with the LFB1 F/R primer set distinguished the 4 Leptospira spp., L. 286 interrogans, L. borgpetersenii, L. kirschneri and L. noguchii, in cultured bacteria and human 287 isolates (Fig. 1). These results are in accordance with those obtained by Naze and 288 collegues<sup>13</sup>. In addition, template-independent amplifications targeting the two relevant 289 genes (Ifb1 and secY) of pathogenic Leptospira spp. also provided a thorough validation of 290 the present HRM assay. The 404 human samples used – paired serum and urine from 202 291

patients, analysed in duplicated (total of 808 specimens) – validate, for the first time, the
 application of HRM as a clinical diagnostic test for human leptospirosis in a clinical setting.

The melting curve analysis of Leptospira species in patient samples (serum and 294 urine) accurately discriminated species when positive controls were included in each run 295 (Fig. 2). According to the T<sub>m</sub>, the HRM assay revealed that 60.9% (28/46) of patients were 296 infected with leptospires belonging to *L. interrogans*, and 39.1% (18/46) were infected with 297 298 leptospires belonging to L. borgpetersenii species (Supplementary Table S2). The most likely explanation for these results is that *L. interrogans* survives longer when exposed to 299 300 the environment, which is why it is more prone than *L. borgpetersenii* to infect humans. The latter does not survive in the environment and is transmitted by direct contact with the 301 host<sup>18</sup>. MAT is the hundred-year old gold standard method for the serodiagnosis of 302 303 leptospirosis and allows for the determination of the presumptive serogroup or serovar of the infecting strain in routine diagnostics and/or epidemiological studies<sup>19</sup>. In the present 304 study, MAT results substantiated the HRM findings, as these patients presented anti-305 Leptospira antibodies belonging to one of these serogroups. In addition, MAT results were 306 positive in only 3/46 (6.5%) of the HRM-positive samples which is expected in recently 307 infected febrile patients and explained by the typical delay period between time of infection 308 and presence of measurable levels of antibodies in blood. Low MAT sensitivity in an early 309 stage of disease infection was discussed previously<sup>20</sup>. In a clinical diagnostic context, this 310 311 observation alone qualifies HRM as a valuable alternative to MAT by providing early unambiguous diagnosis of the disease, which can better inform treatment decisions by the 312 physician as recommended by WHO<sup>3</sup>. The HRM method validated in the present study not 313 314 only detects Leptospira in human biological samples with 100% accuracy, but also informs epidemiology of the disease by identifying the infecting species. 315

By conducting DNA sequencing as part of the assay validation, we determined that the leptospires infecting these patients belonged to the serogroups Icterohaemorrhagiae and Ballum (Fig. 3). These results agree with prior studies performed in the Azores Islands (São Miguel and Terceira), where the serogroups Icterohaemorrhagiae (*L. interrogans*) and Ballum (*L. borgpetersenii*) were the most frequent human<sup>4,15</sup> and rodent *Leptospira* isolates<sup>16,21</sup>.

The profiles based on the 46 confirmed positive patients (by nested PCR and HRM) 322 described in Table 2 are in accordance with the kinetics of *Leptospira* infection and disease 323 324 progression in humans<sup>18</sup>. The analysis allows us to identify the illness point at which patients presented at the hospital. Infection produces leptospiraemia within the first days 325 after exposure, which is followed by the appearance of leptospires in multiple organs by the 326 327 3<sup>rd</sup> day of infection (incubation period and dissemination). Illness develops with the appearance of agglutinating antibodies 5-14 days after exposure (early phase). Leptospires 328 are cleared from the bloodstream and organs in the late phase, as serum agglutinating 329 antibody titres increase<sup>18</sup>. A higher percentage of patients in this study were seen in the 330 early phase of the disease (profile B, Table 2), when the immune system starts to produce 331 antibodies and clearing *Leptospira* from the blood, which is why the bacteria is detected in 332 serum and urine. Another important finding is that HRM is more sensitive than nested PCR 333 at detecting *Leptospira* during the incubation period (first seven days, profile A). This finding 334 335 is of clinical relevance because it allows for the immediate initiation of antibiotic therapy at the earliest onset. Regarding profile C, 23.4% of patients presented at the hospital when 336 Leptospira DNA is detected in the urine. This delay in coming to the hospital probably 337 338 occurs because the symptoms are similar to those of flu, and patients stay at home and take conventional over-the-counter medicine. For patients with profile C, HRM was more 339 specific than nested PCR; one patient was positive by nested PCR and negative by HRM. 340

Bacterial DNA sequencing of this patient's urine sample (#18) showed a 97% match to 341 Collinsella aerofaciens, a type of bacteria found in the human gut, proving that the nested 342 PCR result was a false positive. This finding highlights the caution necessary when 343 interpreting the results of assays such as nested PCR that target the rrs gene (encoding 344 16S rRNA), which is conserved among many bacterial species, and are thus prone to 345 cross-reactivity. Extra care should be taken when validating PCR assays based on the rss 346 347 gene, especially in urine samples that contain poorly characterized microbial flora, which is supported by previous observations<sup>22</sup>. The performance of the HRM assay was evaluated 348 349 and compared with that of the reference molecular test, nested PCR (Table 4); HRM was 100% accurate. The high specificity (100%) and sensitivity (100%) of HRM in endemic 350 regions, such as the Azores, is highly relevant. Notably, since the nested PCR technique 351 352 was implemented at HDES in 2005, no patient on São Miguel Island has died of leptospirosis. According to official data in the Azores (the islands of São Miguel and 353 354 Terceira) for the period between 1986 and 2002, fewer than 19 deaths due to leptospirosis were reported each year<sup>16</sup>. 355

In clinical diagnostic laboratories, real-time PCR methods are increasingly being 356 used instead of conventional PCR methods, providing the opportunity to rapidly confirm 357 leptospirosis infection in the first days of infection. So far, this is the most comprehensive 358 study performed for laboratorial diagnosis of human leptospirosis using paired samples of 359 360 serum and urine from the same patient. HRM allows for accurate clinical diagnosis of leptospirosis in just 2 hours, rather than the 5 hours needed for nested PCR, and the results 361 are unambiguous and easy to interpret. The HRM assay is a robust molecular PCR method 362 363 for the diagnosis of human leptospirosis infection in endemic regions and it can be fully implemented in routine clinical laboratories with real-time PCR equipment. Furthermore, 364 HRM has the advantage of allowing for the distinction of *Leptospira* species which informs 365

leptospirosis epidemiology in the geographic region without requiring the maintenance of large strain collections and labourious cultures. Recently, molecular PCR and serological methods for the diagnosis of human leptospirosis have been published<sup>13, 20, 23-33</sup>. However, their accuracy values are still below those reported here. An important limitation of these serological assays is the inability to detect anti-*Leptospira* antibodies in the very early stages of infection.

In conclusion, we did a unique comparative analysis using a robust biobank of paired samples of serum and urine from the same patient to validate the HRM assay for molecular diagnosis of human leptospirosis in a clinical setting. As a clinical diagnostic method, it is imperative to use both primer sets in each run to amplify the *lfb1* and *secY* genes and to include at least one positive and one negative control. Furthermore, rapidly distinguishing *Leptospira* species while performing the diagnostic test adds an epidemiological advantage to the assay over current clinical molecular diagnostic techniques.

379

### 380 **References**

- 1. Levett, P. N. Leptospirosis. *Clin. Microbiol. Rev.* **14**, 296–326 (2001).
- Collares-Pereira, M. *et al.* First epidemiological data on pathogenic leptospires isolated
   on the Azorean islands. *Eur. J. Epidemiol.* **13**, 435–441 (1997).
- World Health Organization. Human leptospirosis: guidence for diagnosis, surveillance,
   and control. WHO Library, ISBN 924154589 5, 1–107 (2003).
- Gonçalves, A. T. *et al.* First isolation of human Leptospira strains, Azores, Portugal. *Int. J. Infect. Dis.* 14, e148–e153, doi: 10.1016/j.ijid.2009.12.004 (2010).
- 5. Mérien, F., Amouriaux, P., Perolat, P., Baranton, G. & Saint Girons, I. Polymerase chain
  reaction for detection of Leptospira spp. in clinical samples. *J. Clin. Microbiol.* 30,
  2219–2224 (1992).

- 391 6. Tong, S. Y. & Giffard, P. M. Microbiological applications of high-resolution melting
  analysis. *J. Clin. Microbiol.* **50**, 3418–3421, doi: 10.1128/JCM.01709-12 (2012).
- 7. Wittwer, C. T., Reed, G. H., Gundry, C. N., Vandersteen, J. G. & Pryor, R. J. Highresolution genotyping by amplicon melting analysis using LCGreen. *Clin. Chem.* 49,
  853–860, doi: 10.1373/49.6.853 (2003).
- Montgomery, J. L., Sanford, L. N. & Wittwer, C. T. High-resolution DNA melting analysis
   in clinical research and diagnostics. *Expert Rev. Mol. Diagn.* **10**, 219–240, doi:
   10.1586/erm.09.84 (2010).
- 9. Li, B. S. *et al.* Is high resolution melting analysis (HRMA) accurate for detection of
  human disease-associated mutations? A meta analysis. *Plos One.* 6, e28078, doi:
  10.1371/journal.pone.0028078 (2011).
- 402 10. Negru, S. *et al.* KRAS, NRAS and BRAF mutations in Greek and Romanian patients
  403 with colorectal cancer: a cohort study. *BMJ Open.* 4, e004652, doi: 10.1136/bmjopen404 2013-004652 (2014).
- 405 11. Chua, K. H. *et al.* Development of high resolution melting analysis for the diagnosis of
  406 human malaria. *Sci. Rep.* **5**, 15671, doi: 10.1038/srep15671 (2015).
- 407 12. Andini, N. *et al.* Microbial typing by machine learned DNA melt signatures. *Sci. Rep.* 7,
  408 42097, doi: 10.1038/srep42097 (2017).
- 13. Naze, F. Desvars, A., Picardeau, M., Bourhy, P. & Michault, A. Use of new high
  resolution melting method for genotyping pathogenic Leptospira spp. *Plos One.* 10,
  e0127430, doi: 10.1371/journal.pone.0127430 (2015).
- 14. Peláez Sánchez, R. G., Quintero J. Á. L., Pereira, M. M. & Agudelo-Flórez, P. Highresolution melting curve analysis of the 16S ribosomal gene to detect and identify
  pathogenic and saprophytic Leptospira species in colombian isolates. *Am. J. Trop. Med. Hyg.* 96, 1031–1038, doi: 10.4269/ajtmh.16-0312 (2017).

- 15. Esteves, L. *et al.* Human leptospirosis: seroreactivity and genetic susceptibility in the
  population of São Miguel Island (Azores, Portugal). *Plos One.* 9, e108534, doi:
  10.1371/journal.pone.0108534 (2014).
- 16. Vieira, M. L., Gama-Simões, M. J. & Collares-Pereira, M. Human leptospirosis in
  Portugal: a retrospective study of eighteen years. *Int. J. Infect. Dis.* 10, 378–386, doi:
  10.1016/j.ijid.2005.07.006 (2006).
- 422 17. STARD Group. STARD 2015: an updated list of essential items for reporting diagnostic
  423 accuracy studies. *BMJ*. **351**, h5527, doi: 10.1136/bmj.h5527 (2015).
- 424 18.Ko, Al., Goarant C. & Picardeau M. Leptospira: the dawn of the molecular genetics era
- for an emerging zoonotic pathogen. *Nat. Rev. Microbiol.* 10, 736–747, doi:
  10.1038/nrmicro2208 (2009).
- 427 19.Goris, M. G. & Hartskeerl R. A. Leptospirosis serodiagnosis by the microscopic
   428 agglutination test. *Curr. Protoc. Microbiol.* 32, Unit 12E 15 (2014).
- 20. Courdurie, C., Le Govic, Y., Bourhy, P., Alexer, D. & Pailla, K. Evaluation of different
  serological assays for early diagnosis of leptospirosis in Martinique (French West
  Indies). *PLoS Negl. Trop. Dis.* **11**, e0005678, doi: 10.1371/journal.pntd.0005678 (2017).
- 432 21. Collares-Pereira, M., Santos-Reis M., Gonçalves, L., Vieira, M. L. & Flor, L.
  433 Epidemiology and control of leptospirosis in the Azores project. Final scientific report.
- 434 USA Scientific Cooperative Agreement No. 58–401–3–F185, 2003–2008 (2008).
- 22. Villumsen, S. *et al.* Novel TaqMan PCR for detection of Leptospira species in urine and
  blood: pit-falls of in silico validation. *J. Microbiol. Methods.* 91, 184–190, doi:
  10.1016/j.mimet.2012.06.009 (2012).
- 23. Mohd, M. R. et al. Development and validation of pan-Leptospira Taqman qPCR for the
  detection of Leptospira spp. in clinical specimens. *Mol. Cell. Probes.* S08908508(17)30127-5 (2018).

441 24. Waggoner, J.J. et al. Sensitive real-time PCR detection of pathogenic Leptospira spp.

- 442 and a comparison of nucleic acid amplification methods for the diagnosis of 443 leptospirosis. *Plos One.* **9**, e112356, doi: 10.1371/journal.pone.0112356 (2014).
- 444 25. Smythe, L.D. et al. A quantitative PCR (TaqMan) assay for pathogenic Leptospira spp.
- 445 *BMC Infect. Dis.* **2**, 13, doi: 10.1186/1471-2334-2-13 (2002).
- 26. Riediger, I.N. et al. Rapid, actionable diagnosis of urban epidemic leptospirosis using a
  pathogenic Leptospira lipL32-based real-time PCR assay. *PLoS Negl. Trop. Dis.* 9,
  e0005940, doi: 10.1371/journal.pntd.0005940 (2017).
- 27. Stoddard, R.A., Gee, J.E., Wilkins, P.P., McCaustland, K. & Hoffmaster, A.R. Detection
- 450 of pathogenic Leptospira spp. through TaqMan polymerase chain reaction targeting the
- 451 LipL32 gene. *Diagn. Microbiol. Infect. Dis.* 3, 247–55, doi:
  452 10.1016/j.diagmicrobio.2009.03.014 (2009).
- 28. Backstedt, B.T. et al. Efficient detection of pathogenic leptospires using 16S ribosomal
  RNA. *PLoS One.* **10**, e0128913, doi: 10.1371/journal.pone.0128913 (2015).
- 455 29. Ahmed, A., Engelberts, M.F., Boer, K.R., Ahmed, N. & Hartskeerl, R.A. Development 456 and validation of a real-time PCR for detection of pathogenic Leptospira species in
- 457 clinical materials. *PLoS One.* **4**, e7093, doi: 10.1371/journal.pone.0007093 (2009).
- 30. Merien, F. et al. A rapid and quantitative method for the detection of Leptospira species
  in human leptospirosis. *FEMS Microbiol. Lett.* **249**, 139–47 (2005).
- 31. Dittrich, S. et al. A prospective hospital study to evaluate the diagnostic accuracy of
  rapid diagnostic tests for the early detection of leptospirosis in Laos. *Am. J. Trop. Med. Hyg.* [Epub ahead of print], doi: 10.4269/ajtmh.17-0702 (2018).
- 32. Nabity, S.A. et al. Prospective evaluation of accuracy and clinical utility of the Dual Path
   Platform (DPP) assay for the point-of-care diagnosis of leptospirosis in hospitalized

465 patients. *PLoS Negl. Trop. Dis.* **12**, e0006285, doi: 10.1371/journal.pntd.0006285
466 (2018).

33. Niloofa, R. et al. Diagnosis of leptospirosis: comparison between Microscopic
Agglutination Test, IgM-ELISA and IgM Rapid Immunochromatography Test. *PLoS One.*10, e0129236, doi: 10.1371/journal.pone.0129236 (2015).

470

#### 471 Acknowledgements

The present work was supported by grants from the Direção Regional da Ciência e Tecnologia (M121/I/OLD/2002, from the Azores Government) and BioISI (Centre Reference: UID/MULTI/04046/2013) from FCT/MCTES/PIDDAC, Portugal. The authors would like to thank Rúben Neves, a Ph.D. student at Clark University, for revising the English language of the manuscript.

477

#### 478 Author Contributions

L.M.E. and L.M.V. designed the study and wrote the manuscript, L.M.V. provided materials and reagents, M.L.V. provided the *Leptospira* strains and human isolates, M.L.V. and T.C. performed and analysed the MAT experiments, L.M.E. performed and analysed the HRM experiments, S.M.B. performed and analysed the sequencing experiments, C.C.B. tested and calibrated High Resolution Melt software v3.0.1 (Applied Biosystems), and M.G.S. provided critical reading and editing of the manuscript. All authors read, edited and approved the final manuscript.

486

### 487 Data availability

All data generated or analysed during this study are included in this published article andthe Supplementary Information files.

#### 490

# 491 Additional Information

492 **Supplementary information** accompanies this paper.

- 494 **Competing financial interests.** The authorities who provided funding for this project had
- 495 no role in the study design, data collection and analysis, decision to publish, or preparation
- 496 of the manuscript.

#### 497 Figure legends

Figure 1. High resolution melting curve analysis profiles of cultured *Leptospira* spp.,
and *Leptospira* isolates from human leptospirosis patients. (a) HRM profiles using the
LFB1 primer pair; (b) HRM profiles using the G1/G2 primer pair. Abbreviations: HI1, Human
isolate 1; HI6, Human isolate 6.
Figure 2. High resolution melting curve analysis profiles of human clinical samples

(serum and urine) from patients with suspected leptospirosis. (a) HRM profiles using
the LFB1 primer pair; (b) HRM profiles using the G1/G2 primer pair.

506

**Figure 3. Confirmation of the HRM analysis by Sanger sequencing.** Alignment of the consensus sequences of the clinical samples, *Leptospira* spp. and human isolates. Only the sequences showing differences from the first sequence are shown. Nucleotides identical to those in the first sequence are indicated by dots.

# 511 Tables

					HRM (primers)								
	Con	ventiona	al neste	ed PCR	LFB1				G1/G2				
Patients	Ро	sitive	Neg	Negative		Positive		Negative		Positive		Negative	
(N = 202)	Ν	%	Ν	%	N	N %		%	Ν	%	Ν	%	
Total	47	23.3	155	76.7	46	22.7	156	77.3	46	22.7	156	77.3	
Duplicate s	Duplicate samples (N = 808)												
Serum													
S1	33	16.3	169	83.7	32	15.8	170	84.2	33	16.3	169	83.7	
S2	34	16.8	168	83.2	26	12.9	176	87.1	30	14.9	172	85.1	
Urine													
U1	35	17.3	167	82.7	27	13.4	175	86.6	30	14.9	172	85.1	
U2	30	14.9	172	85.2	25	12.4	177	87.6	25	12.4	177	87.6	

Table 1. Molecular characterization of 202 patients with suspected clinicalleptospirosis. Duplicate serum and urine samples were investigated byconventional nested PCR and HRM methods.

512

513

#### Leptospira detection methods Conventional **HRM (primers)** nested PCR MAT LFB1 Kinetics of Leptospira infection (16S RNA) G1/G2 **Molecular profiles** Phases **Kinetics** Ν Ν Ν % % Ν % % Positive patients (after Sanger sequencing) 46 100 46 100 46 100 6 13.0 Profile A: Blood (serum + / urine -)Incubation 8 17.4 16 34.8 14 30.4 0 Onset 0.0 Profile B: Blood and urine (serum + / urine +) Early Clearance 28 60.9 18 39.1 22 47.8 2 4.3 Profile C: Urine Late (kidney colonization) 26.1 8.5 (serum - / urine +) Excretion 10 21.7 12 10 21.7 4

Table 2. Molecular profiles of patients with laboratory-confirmed leptospirosis and the corresponding disease kinetics. P > 0.05, conventional nested PCR compared with HRM; P < 0.0001, HRM compared with MAT.

514

515

516

518	Kinetics	s of Leptospira infection	Serovar	Species	
519	Profiles	Conventional nested PCR (N = 46)	МАТ	HRM	
520	С	1	Positive (co-agglutination – highest titre 1:1280 against Arb A and Cyn)	L. borgpetersenii	
521		1	Positive (Arb A 1:160)	L. borgpetersenii	
522		1	Positive (co-agglutination – highest titre 1:320 against Arb A 1:320)	L. interrogans	
		1	NC	L. borgpetersenii	
523		6	Negative	L. interrogans	
524	В	1	NC	L. interrogans	
521		1	NC	L. interrogans	
525		16	Negative	L. interrogans	
526		10	Negative	L. borgpetersenii	
520	А	3	Negative	L. interrogans	
527		5	Negative	L. borgpetersenii	

 Table 3. MAT results from the 46 patients with laboratory-confirmed leptospirosis. Abbreviations: Arb A [serovar Arborea (Azorean isolate)
 serogroup Ballum]; Cyn [Cynopteri (reference serovar) serogroup Cynopteri];
 NC, not conclusive (specific reactivity below the cut-off of 1:160 adopted in the Azorean endemic region).

# 531

532

	HRM			
Patients (N = 202)	Estimated value	95% CI		
Sensitivity	1.00	0.90–1.00		
Specificity	1.00	0.97–1.00		
Positive predictive value (PPV)	1.00	0.90–1.00		
Negative predictive value (NPV)	1.00	0.97–1.00		
Accuracy (%)	100	_		


Table 4. Diagnostic accuracy of HRM analysis comparedwith conventional nested PCR for detecting humanleptospirosis infection. Abbreviation: CI, confidence interval.


	Clinical samples		Leptospira		Diagnostic accuracy						
Patients (N)	Serum (N)	Urine (N)	Detection method	Molecular target	Strains identified (N)	Sensitivity	Specificity	Positive Predictive Value (PPV)	Negative Predictive Value (NPV)	Country (geographic area)	Paper (year)
Mole	Molecular PCR methods										
202	202*	202*	High Resolution Melting (HRM)	lfb1 and secy	4	100 (90-100)	100 (97-100)	100 (90-100)	100 (97-100)	Portugal (Azores Islands)	Current study
42	42	0	High Resolution Melting (HRM)	Ifb1 and secy	49	NR	NR	NR	NR	France (Reunion Island)	Naze F et al 2015 <sup>13</sup>
58	0	58	Taqman qPCR	<i>lipL3</i> 2 16S rRNA	29	NR	100 (88-100) 97 (83-99)	NR	NR	Denmark	Villumsen S et al 2012 <sup>22</sup>
65	65	0	Taqman qPCR	rrs	31	NR	NR	NR	NR	Malaysia	Mohd Ali MR et al. 2018 <sup>23</sup>
63	63	0	Taqman qPCR	16S rRNA	23	NR	NR	NR	NR	USA	Waggoner JJ et al 2014 <sup>24</sup>
67	66	1	Taqman qPCR	16S rRNA	29	NR	NR	NR	NR	Australia	Smythe LD et al 2002 <sup>25</sup>
150	150	0	Taqman qPCR	lipL32	1	29.1 (21.6–38.0)	NR	NR	NR	Brazil (Salvador and Curitiba)	Riediger IN et al 2017 <sup>26</sup>
7	7	1	Taqman qPCR	lipL32	22	100	100	NR	NR	USA	Stoddard RA et al 2009 <sup>27</sup>
25	25	0	SYBR Green-based qRT-PCR	16S rRNA	22	NR	NR	NR	NR	USA	Backstedt BT et al 2015 <sup>28</sup>
133	133	0	SYBR Green-based qRT-PCR	secy	56	100 (70–100)	100 (93–100)	NR	NR	The Netherlands	Ahmed A et al 2009 <sup>29</sup>
61	61	0	SYBR Green-based qRT-PCR	lfb1	24	NR	NR	NR	NR	France	Merien F et al 2005 <sup>30</sup>
Serol	ogical met	hods									
695	695	0	Test-it Leptorapide Dual Path Platform SD-IgM	IgM IgM IgM IgM	0	71.0 (41.9–91.6) 47.4 (24.5–71.1) 35.0 (15.4–59.2) 21.1 (6.1–45.6)	64.6 (59.8–69.3) 77.2 (73.1–80.9) 62.1 (57.7–66.4) 94.8 (92.6–96.7)	NR	NR	Laos	Dittrich S et al. 2018 <sup>31</sup>
98	98	0	Dual Path Platform IgM-ELISA	lgM + lgG lgM	0	85.2 (66.3-95.7) 80.8 (60.7-93.5)	87.2 (74.2-95.1) 100.0 (92.2-100.0)	79.3 (60.3-92.0) 100.0 (83.9-100.0)	91.1 (78.8-97.5) 90.2 (78.6-96.7)	Brazil (Salvador)	Nabity SA et al. 2018 <sup>32</sup>
103	103	0	ELISA Serion ELISA-Hb Pasteur GenBio ImmunoDOT	IgM IgM IgM	68	75 (66–83) 67 (57–75) 69 (59–76)	92 (85–95) 98 (94–100) 100 (97–100)	NR	NR	France (Martinique, West Indies)	Courdurie C et al. 2017 <sup>20</sup>
888	888	0	MAT ELISA Serion Leptocheck-WB	lg IgM IgM	0	100 80.2 (75.6–84.2) 80.8 (76.2–84.7)	100 88.5 (85.4–91.1) 76.9 (73.0–80.4)	100 82.6 (78.0–86.3) 70.3 (65.5–74.6)	100 86.9 (83.7–89.6) 85.6 (82.0–88.5)	Sri Lanka	Niloofa R et al 2015 <sup>33</sup>

 Table 5. Comparison between molecular and serological assays for the diagnosis of leptospirosis. \*Analysed in duplicated; NR, not reported.


 534


erivative Reporter (-Rn)





ь





L.borpetersenii sg. Ballum	IGCAAGTCAAGCGGAGTAGCAATACTCAGCGGCGAACGGGTGAGTAACACGTGGGTAATCTTCCTCCGAGTCTGGGATAACTTTCCGAAAGGGGAGCTAAT
Human Isolate 6	
Clinical sample #1 U1	
Clinical sample #2 S1	
Clinical sample #3 S2	
Clinical sample #4 S1	
Clinical sample #5 S2	
Clinical sample #6 U1	
Clinical sample #7 S1	
Clinical sample #8 S2	
Clinical sample #9 S1	
Clinical sample #10 S2	
L interrogans sg Icterohaemorragiae	Т
Human Isolate 1	
Clinical sample #11 S1	ТА
Clinical sample #12 S2	ТА
Clinical sample #13 S2	ТА
Clinical sample #14 U1	ТА
Clinical sample #15 S2	ТА
Clinical sample #16 U1	
Clinical sample #17 S1	ТА
Clinical sample #18 U1	GCG.CGCGT.TT.AACATGCA.GGAAC.GC.C.CKYCYYCGGRI/GGAA.C.AGTGGCGAACGGCT.AG.AAC.CGTGGAGAACCTGCCCCCT.CCCC
	THE PERCENT OF THE PERCENT
D. B.	
L borpetersenii sg. Ballum Human Isolate 6	ACTGGATAGTCCCCGAGAGGTCATAGGATTTTTCCGGGTAAAGATTTATTGCTCGGAGATGAGCCCGCCGCCCGATTAGCTAGTGGTGAGGTAATGGCTCAC
Clinical sample #1 U1	
Clinical sample #1 01 Clinical sample #2 S1	
Clinical sample #2 S1 Clinical sample #3 S2	
Clinical sample #3 52 Clinical sample #4 S1	***************************************
Clinical sample #6 S2	
Clinical sample #6 U1	
Clinical sample #7 S1	
Clinical sample #8 S2	
Clinical sample #9 S1	
Clinical sample #10 S2	
L interrogans so Icterohaemorragiae	G A A A
Human Isolate 1	G A A T A
Clinical sample #11 S1	G A A T A
Clinical sample #12 S2	G A
Clinical sample #13 S2	G
Clinical sample #14 U1	G
Clinical sample #15 S2	G
Clinical sample #16 U1	
Clinical sample #17 S1	G
Clinical sample #18 U1	SGGAT.GCCGAA.GGGTA.ACCGGATACCCC.GGG.GCC.AT.CACCCCC.G.TAAAG.CCGAC.GG.AGGA.GCTCCGCC.T
-	
L.borpetersenii sg. Ballum Human Isolate 6	CAAGGCGACGATCGGTAGCCGGCCTGAGAGGGTGTTCGGCCACAATGGAACTGAGACACGGTCCATACTCCTACGGGAGGCAGCAGTTAAG
Clinical sample #1 U1	
Clinical sample #1 01 Clinical sample #2 S1	
Clinical sample #2 S1 Clinical sample #3 S2	
Clinical sample #3 S2 Clinical sample #4 S1	***************************************
Clinical sample #6 S2	***************************************
Clinical sample #6 U1	
Clinical sample #7 S1	
Clinical sample #8 S2	
Clinical sample #9 S1	
Clinical sample #10 S2	
L interrogans so Icterohaemorragiae	
Human Isolate 1	
Clinical sample #11 S1	
Clinical sample #12 S2	
Clinical sample #13 S2	
Clinical sample #14 U1	
Clinical sample #15 S2	
Clinical sample #16 U1	
Clinical sample #17 S1	
Clinical sample #18 U1	G.TAGCGGT.ACACCGT.CC.ACAACGGGT.GCC.GGT.